These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 33377156)

  • 1. Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    Kuji S; Kondo H; Ohara T; Deura I; Tozawa-Ono A; Migita O; Kawamoto H; Tsugawa K; Chosokabe M; Koike J; Maeda I; Suzuki N
    Jpn J Clin Oncol; 2021 Mar; 51(3):492-497. PubMed ID: 33377156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
    Abay M; Ozgen L; Yalcin Y; Ozerkan K
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
    J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
    Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
    Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
    Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
    Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
    Brown JV; Epstein HD; Mattison JN; Micha JP; Rettenmaier MA; Goldstein BH
    J Minim Invasive Gynecol; 2008; 15(6):749-51. PubMed ID: 18971141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
    N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
    Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
    JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
    Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
    Kobayashi Y; Hirasawa A; Chiyoda T; Ueki A; Masuda K; Misu K; Kawaida M; Hayashi S; Kataoka F; Banno K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):213-217. PubMed ID: 33037428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    Cheng A; Li L; Wu M; Lang J
    Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of
    Stroot IAS; Brouwer J; Bart J; Hollema H; Stommel-Jenner DJ; Wagner MM; van Doorn HC; de Hullu JA; Gaarenstroom KN; Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez Garcia EB; Ausems MGEM; Boere IA; van Engelen K; van Asperen CJ; Schmidt MK; Wevers MR; de Bock GH; Mourits MJE;
    J Clin Oncol; 2023 May; 41(14):2523-2535. PubMed ID: 36809028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to risk-reducing salpingo-oophorectomy guidelines among gynecologic oncologists compared to general gynecologists.
    Blustein P; Werner SR; Uppalapati P; Leung TM; Husk GA; Pereira EB; Whyte JS; Villella JA
    Am J Obstet Gynecol; 2023 Sep; 229(3):280.e1-280.e8. PubMed ID: 37308046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    Minig L; Cabrera S; Oliver R; Couso A; Rubio MJ; Iacoponi S; Martin-Salamanca MB; Carballo-Rastrilla S; Cádenas-Rebollo JM; García-Garcia A; Gil-Ibáñez B; Juan-Fita MJ; Patrono MG
    Clin Transl Oncol; 2018 Oct; 20(10):1337-1344. PubMed ID: 29623583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.